Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLR 125 in Relapsed or Refractory Triple Negative Breast Cancer
NCT07311993Phase 1Recruiting
- Sponsor
- Cellectar Biosciences
- Start
- Dec 2025
- Primary completion
- Feb 2028
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of CLR 121125 in triple-negative breast cancer (TNBC) (5 arms), sponsored by Cellectar Biosciences. Primary endpoints: Dose Determination for CLR 125 at 57 days and Number of adverse events related to study treatment at 1 year. Started Dec 2025; status: recruiting.
02
Drugs
CLR 121125
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07311993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07311993.